Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
过去一年中，多名再生元制药股份有限公司 (NASDAQ:REGN) 内部人士出售了大量股票，这可能引起投资者的关注。分析内部交易时，了解内部人员是否购买股票通常比了解他们是否出售更有价值，因为出售可能会传递模糊信息。然而，当多个内部人员在一定时间内出售股票时，股东应该注意到，这可能是一个红旗。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
尽管我们永远不会建议投资者仅基于公司董事的行动做出决策，但逻辑推断您应该关注内部人士是否买卖股票。
Regeneron Pharmaceuticals Insider Transactions Over The Last Year
过去一年中再生元制药公司的内部交易
Over the last year, we can see that the biggest insider sale was by the Executive VP and GM of Industrial Operations & Product Supply, Daniel Van Plew, for US$9.8m worth of shares, at about US$952 per share. That means that an insider was selling shares at slightly below the current price (US$1,100). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 24% of Daniel Van Plew's holding.
过去一年，我们可以看到最大的内部人员销售来自产业运营和产品供应的执行副总裁兼总经理丹尼尔·范普鲁，总价值980万美元的股份，每股约952美元。这意味着内部人员在略低于当前价格（1100美元）的价格上出售了股份。一般来说，当内部人员以低于当前价格出售股票时，我们认为这是令人沮丧的，因为这表明他们对低估值感到满意。虽然内部人员的卖出并不是一个积极的信号，但我们不能确定它是否意味着内部人员认为这些股票已经完全价值，因此这只是一个微弱的信号。值得注意的是，这次销售仅占丹尼尔·范普鲁持有的24%。
Insiders in Regeneron Pharmaceuticals didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
在过去一年中，再生元制药的内部人士没有购买任何股票。下图显示了过去一年中公司和个人的内部交易。单击下面的图表，您可以查看每个内部交易的详细信息！
I will like Regeneron Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我看到内部人员进行大规模股票买入，我会更喜欢再生元制药。在等待的同时，请查看这份免费的低估和小盘股票列表，其中有相当数量的最近内部买入。
Insider Ownership Of Regeneron Pharmaceuticals
再生元制药的内部所有权
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Regeneron Pharmaceuticals insiders own 4.0% of the company, worth about US$4.8b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
对于普通股东来说，了解公司内部人员持有多少股份很有价值，因为高内部所有权通常使公司领导层更加关注股东利益。再生元制药内部人员拥有公司的4.0%股份，价值约48亿美元，这是一个好的迹象，股东会感到高兴，因为这表明管理层的利益与其他股东的利益是一致的。
So What Do The Regeneron Pharmaceuticals Insider Transactions Indicate?
那么，再生元制药的内部交易意味着什么？
It doesn't really mean much that no insider has traded Regeneron Pharmaceuticals shares in the last quarter. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Regeneron Pharmaceuticals insider transactions don't fill us with confidence. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
实际上，上个季度内没有内部人员交易再生元制药股票并不意味着什么。内部人员拥有大量股票是令人鼓舞的，但是我们希望看到更多的内部买入，因为过去一年的再生元制药内部交易并没有让我们充满信心。如果您和我一样，您可能会想到这家公司会增长还是缩小。幸运的是，您可以查看这份为其未来提供分析师预测的免费报告。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潜在具有优秀财务状况的公司-请不要错过这个带有高股权回报率和低债务的有趣公司免费列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言，内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？对内容感到担忧？请直接与我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？对内容感到担忧？请直接与我们联系。或者，发送电子邮件至editorial-team@simplywallst.com。